

FIG. 1




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

# ADRIATIC study design

Phase 3, randomized, double-blind, placebo-controlled, multicenter, international study (NCT03703297)




FIG. 9

Baseline characteristics

|                                    | Durvalumab<br>(n=264)                       | Placebo<br>(n=266) |                    |
|------------------------------------|---------------------------------------------|--------------------|--------------------|
| Age                                | Median (range), years                       | 62.0 (28–84)       | 62.0 (28–79)       |
| Sex, %                             | Male / Female                               | 67.4 / 32.6        | 70.7 / 29.3        |
| Race, %                            | White / Asian / Other                       | 49.2 / 49.6 / 1.1  | 51.5 / 45.5 / 3.0  |
| WHO PS, %                          | 0 / 1                                       | 50.0 / 50.0        | 47.4 / 52.6        |
| Smoking status, %                  | Current / Former / Never                    | 23.9 / 67.4 / 8.7  | 20.7 / 69.5 / 9.8  |
| AJCC disease stage at diagnosis, % | I / II / III                                | 3.0 / 9.5 / 87.5   | 4.1 / 8.6 / 87.2   |
| Prior chemotherapy regimen, %*     | Cisplatin-etoposide / Carboplatin-etoposide | 65.5 / 34.5        | 66.9 / 33.1        |
| Prior radiation schedule, %        | QD / BID                                    | 73.9 / 26.1        | 70.3 / 29.7        |
| Best response to prior cCRT, %     | CR / PR / SD                                | 11.7 / 72.3 / 15.9 | 12.8 / 75.2 / 12.0 |
| Prior PCI, %                       | Yes / No                                    | 53.8 / 46.2        | 53.8 / 46.2        |

FIG. 10

Patient disposition

|                                                      | Durvalumab<br>(n=264) | Placebo<br>(n=265) |
|------------------------------------------------------|-----------------------|--------------------|
| Received treatment, n (%)                            | 263 (99.6)            | 265 (99.6)         |
| Ongoing study treatment at DCO*, n (%)               | 0                     | 0                  |
| Completed the maximum 24 months of treatment, n (%)  | 88 (33.5)             | 70 (26.4)          |
| Discontinued study treatment, n (%)                  | 175 (66.5)            | 195 (73.6)         |
| Disease progression                                  | 121 (46.0)            | 154 (58.1)         |
| Adverse event                                        | 43 (16.3)             | 29 (10.9)          |
| Patient decision                                     | 10 (3.8)              | 11 (4.2)           |
| Other reason                                         | 1 (0.4)               | 1 (0.4)            |
| Ongoing study (in follow-up) at DCO*, n (%)          | 140 (53.0)            | 111 (41.7)         |
| Received subsequent systemic anticancer therapy, n   | 95                    | 127                |
| Received immunotherapy as first subsequent treatment | 17                    | 31                 |

FIG. 11

Overall survival (dual primary endpoint)

• Median duration of follow up in censored patients: 37.2 months (range 0.1–60.9)





FIG. 12  
OS subgroup analysis



**FIG. 13**  
**Progression-free survival\* (dual primary endpoint)**

\* Median duration of follow up in censored patients: 27.6 months (range 0.0–55.8)




FIG. 14  
PFS subgroup analysis





FIG. 15

Exposure and safety summary

|                                          | Durvalumab<br>(n=263)     |  | Placebo<br>(n=266) |  |
|------------------------------------------|---------------------------|--|--------------------|--|
| Number of durvalumab or placebo doses    | Median (range)            |  | 9.0 (1-26)         |  |
|                                          | Mean (standard deviation) |  | 12.9 (9.6)         |  |
| Any-grade all-cause AEs, n (%)           | 248 (94.3)                |  | 234 (88.3)         |  |
| Maximum grade 3/4 AEs                    | 64 (24.3)                 |  | 64 (24.2)          |  |
| Serious AEs                              | 78 (29.7)                 |  | 64 (24.2)          |  |
| AEs leading to treatment discontinuation | 43 (16.3)                 |  | 28 (10.6)          |  |
| AEs leading to death                     | 7 (2.7)                   |  | 5 (1.9)            |  |
| Treatment-related* AEs leading to death  | 2 (0.8)†                  |  | 0                  |  |
| Any-grade immune-mediated AEs†           | 84 (31.9)                 |  | 27 (10.2)          |  |
| Maximum grade 3/4 immune-mediated AEs    | 14 (5.3)                  |  | 4 (1.5)            |  |

**FIG. 16**  
**Most frequent AEs\***



**FIG. 17**  
**Pneumonitis/radiation pneumonitis**

| Pneumonitis or radiation pneumonitis (grouped terms*), n (%) | Durvalumab (n=263) | Placebo (n=266) |
|--------------------------------------------------------------|--------------------|-----------------|
| Any grade                                                    | 100 (38.0)         | 80 (30.2)       |
| Maximum grade 3/4                                            | 8 (3.0)            | 7 (2.6)         |
| Leading to death                                             | 1 (0.4)            | 0               |
| Leading to treatment discontinuation                         | 23 (8.7)           | 8 (3.0)         |